Top
image credit: Pixabay

New type 2 diabetes drug associated with reduced risk of heart failure and death

August 29, 2019

The new type of drugs for type 2 diabetes, the so-called SGLT2 inhibitors, are associated with a reduced risk of heart failure and death as well as of major cardiovascular events, a major Scandinavian registry study led from Karolinska Institutet reports in The BMJ.

Cardiovascular disease is a serious complication of type 2 diabetes. The new SGLT2 inhibitors, which are now a commonly used drug group, reduce blood glucose. Clinical studies have also shown that SGLT2 inhibitors can reduce the risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk.

Read More on The Medical News